PRTT.US Protect Pharmaceutical Corporation
- Market cap
- USD 3.27M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PRTT.US undervalued?
Graham numberThe Graham number of Protect Pharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Protect Pharmaceutical Corporation fundamental analysis
No fundamental analysis for Protect Pharmaceutical Corporation yet.
Protect Pharmaceutical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Protect Pharmaceutical Corporation
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Cor…
Full company profileProtect Pharmaceutical Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Protect Pharmaceutical Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | - | 5.94M | 78.8M | 81.8M | 136M | 132M | - | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | 5.86M | 44.4M | 41.6M | 73.3M | 72.6M | - | - |
| Operating Income | -30.0K | -41.7K | -115K | -1.87K | 5.81M | 27.9M | 25.3M | 47.5M | 57.6M | -3.00K | -43.0K |
| EBITDA | 575K | -41.7K | -115K | -1.87K | 5.81M | 28.1M | 25.5M | 47.7M | 57.6M | -3.00K | -43.0K |
| Net Income | -635K | -41.7K | -123K | -1.87K | 5.81M | 20.2M | 22.4M | 45.9M | 56.3M | -333M | -43.0K |
| EPS | -1.44 | -0.04 | -0.11 | 0.00 | 0.11 | 0.36 | 0.43 | 0.80 | 0.98 | -5.79 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 7.00 | 0.00 | 0.00 | 141K | 20.0M | 366M | 344M | 366M | 418M | - | - |
| Total Liabilities | 100K | 20.8K | 143K | 64.1K | 14.1M | 161M | 114M | 90.0M | 84.9M | - | - |
| Shareholders' Equity | -100K | -20.8K | -143K | -54.3K | 5.89M | 206M | 230M | 276M | 333M | - | - |
| Cash & Short-term Investments | 7.00 | 0.00 | 0.00 | 253.00 | 74.5K | 77.4M | 46.6M | 65.1M | 73.9M | - | - |
| Total Debt | - | - | 101K | - | 14.1M | 12.3M | 2.66M | 3.79M | 3.83M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.8K | -14.2K | 0.00 | 12.0K | 6.77M | 10.5M | -67.2M | 4.04M | 12.7M | - | 662K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 19.8M | 75.4M | 1.82M | 4.04M | 2.53M | - | 5.96M |
| Free Cash Flow | -17.8K | -14.2K | 0.00 | 12.0K | -13.0M | -64.9M | -69.0M | 4.04M | 10.2M | - | -5.30M |
| Ratios | |||||||||||
| ROE | - | - | - | - | 98.7% | 9.8% | 9.8% | 16.6% | 16.9% | - | - |
| ROA | -9,071,428.6% | - | - | -1.3% | 29.0% | 5.5% | 6.5% | 12.5% | 13.5% | - | - |
| Net Profit Margin | - | - | - | - | 97.8% | 25.6% | 27.4% | 33.7% | 42.6% | - | - |
| Debt to Equity | - | - | - | - | 2.39x | 0.06x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Protect Pharmaceutical Corporation dividends
Protect Pharmaceutical Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1000 on Nov 4, 2014.
Who owns Protect Pharmaceutical Corporation
- Insiders 84.31%
- Institutions 0.00%
- Public & others 15.69%
- Shares outstanding 57.5M
- Free float 19.0M
Protect Pharmaceutical Corporation company profile
- Company name
- Protect Pharmaceutical Corporation
- Ticker
- PRTT.US
- Exchange
- USA Stocks
- Sector
- Industrials
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 4876 Cecile Avenue, Las Vegas, NV, United States, 89115
- Phone
- 954 292 0033
- Website
- agropharmacy.com
About Protect Pharmaceutical Corporation
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.
Protect Pharmaceutical Corporation management
2- Mr. Alan CrooksCEO & Director
- Mr. Ali YildizPresident